Scinai Immunotherapeutics SCNI Q4 2023 Earnings NarrowerThanExpected Loss Amid Operational Adjustments FSP Q4 2025 Earnings Significant EPS Beat Masks Revenue Disclosures ROP Q1 2026 Earnings EPS Beat of 258 Highlights Operational Strength SEPN Q1 2026 Earnings SmallerThanExpected Loss Amidst Pipeline Progress ETR Q1 2026 Earnings EPS Slightly Misses Estimates Amid Operational Challenges NEON Q1 2026 Earnings EPS Misses Estimates Amid Elevated Operating Costs